Your browser is no longer supported. Please, upgrade your browser.
Settings
IMMU Immunomedics, Inc. daily Stock Chart
IMMU [NASD]
Immunomedics, Inc.
Index- P/E- EPS (ttm)-1.12 Insider Own6.84% Shs Outstand109.76M Perf Week-0.81%
Market Cap938.45M Forward P/E- EPS next Y-0.56 Insider Trans0.00% Shs Float101.02M Perf Month-0.12%
Income-115.90M PEG- EPS next Q-0.12 Inst Own66.90% Short Float33.44% Perf Quarter52.68%
Sales3.40M P/S276.01 EPS this Y-21.10% Inst Trans0.67% Short Ratio12.16 Perf Half Y86.68%
Book/sh-1.22 P/B- EPS next Y47.70% ROA-227.90% Target Price12.50 Perf Year222.64%
Cash/sh0.42 P/C20.40 EPS next 5Y- ROE138.50% 52W Range2.02 - 9.51 Perf YTD132.97%
Dividend- P/FCF- EPS past 5Y-26.90% ROI-132.90% 52W High-10.09% Beta1.69
Dividend %- Quick Ratio0.60 Sales past 5Y-26.10% Gross Margin66.40% 52W Low323.27% ATR0.47
Employees131 Current Ratio0.60 Sales Q/Q44.40% Oper. Margin- RSI (14)48.68 Volatility4.67% 5.44%
OptionableYes Debt/Eq- EPS Q/Q-272.30% Profit Margin- Rel Volume0.47 Prev Close8.80
ShortableYes LT Debt/Eq- EarningsAug 16 AMC Payout- Avg Volume2.78M Price8.55
Recom1.30 SMA20-2.58% SMA504.03% SMA20058.68% Volume1,298,080 Change-2.84%
May-05-17Upgrade Wells Fargo Market Perform → Outperform
Oct-06-16Resumed Jefferies Buy
Jun-21-16Downgrade Wells Fargo Outperform → Market Perform
May-06-16Upgrade Jefferies Hold → Buy
Dec-04-15Downgrade Wells Fargo Outperform → Market Perform
Jul-29-15Downgrade Jefferies Buy → Hold
Aug-27-14Downgrade R. F. Lafferty Buy → Neutral $4
Jan-08-14Initiated Chardan Capital Markets Buy $9
Oct-02-13Reiterated Oppenheimer Outperform $6 → $8
Sep-10-13Initiated R. F. Lafferty Buy $8
Jun-03-13Initiated WallachBeth Buy $6
Aug-31-11Initiated Summer Street Research Buy $8
Jul-28-11Initiated Summer Street Research Buy $8
Jul-13-11Resumed Brean Murray Buy $8
May-17-11Initiated Oppenheimer Outperform $6
Feb-23-11Initiated Wedbush Outperform $6
Jul-03-07Initiated Brean Murray Buy $8
Feb-20-07Initiated Lazard Capital Buy $6
Jul-10-17 02:40PM  ETFs with exposure to Immunomedics, Inc. : July 10, 2017 Capital Cube
09:00AM  Published Results from Clinical Trials Demonstrate Therapeutic Potential for Immunomedics Sacituzumab Govitecan (IMMU-132) in the Treatment of Metastatic Solid Cancers GlobeNewswire
Jun-29-17 03:11PM  Immunomedics Announces Results of Special Stockholder Meeting GlobeNewswire
08:35AM  Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock Zacks
Jun-27-17 03:20PM  ETFs with exposure to Immunomedics, Inc. : June 27, 2017 Capital Cube
Jun-16-17 03:54PM  ETFs with exposure to Immunomedics, Inc. : June 16, 2017 Capital Cube
Jun-07-17 11:05AM  Three Junior Biotechs Ready to Run Investopedia
Jun-05-17 02:22PM  ETFs with exposure to Immunomedics, Inc. : June 5, 2017 Capital Cube
Jun-01-17 08:00AM  Immunomedics to Present at Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-26-17 09:33AM  Biotech Movers: Immunomedics, Aerie, Exelixis TheStreet.com
May-25-17 12:41PM  ETFs with exposure to Immunomedics, Inc. : May 25, 2017 Capital Cube
May-24-17 09:51AM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q3, 2017 By the Numbers : May 24, 2017 Capital Cube
May-18-17 05:00AM  Edited Transcript of IMMU earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents
May-11-17 09:21PM  Edited Transcript of IMMU earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents +6.14%
May-10-17 04:10PM  Immunomedics reports 3Q loss Associated Press
04:00PM  Immunomedics Announces Third Quarter Fiscal 2017 Results and Clinical Program Developments GlobeNewswire
08:15AM  Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2017 Results GlobeNewswire
May-08-17 05:53PM  The Head-Scratching Reason Immunomedics Rose by as Much as 12% Motley Fool +8.02%
08:25AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : May 8, 2017 Capital Cube
08:00AM  Today's Research Report on Biotech Stocks to Watch: Immunomedics and Esperion Therapeutics Accesswire
06:00AM  Immunomedics Breaks Out, But Will It Last? Investopedia
May-06-17 09:10AM  Did Immunomedics Rise Too Much as Seattle Genetics Deal Terminated? 24/7 Wall St.
May-05-17 04:32PM  Immunomedics, Seattle Genetics Scrap License Deal TheStreet.com +17.56%
04:22PM  Why Immunomedics, MercadoLibre, and Pearson Jumped Today Motley Fool
01:57PM  Why Immunomedics, Inc. Rocketed Today Motley Fool
10:42AM  Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated TheStreet.com
08:46AM  Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value Business Wire
Apr-25-17 04:18PM  Immunomedics, Inc. Value Analysis (NASDAQ:IMMU) : April 25, 2017 Capital Cube +6.98%
Apr-24-17 08:41AM  Immunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : April 24, 2017 Capital Cube
Apr-21-17 06:52PM  Why Immunomedics, Inc. Got Hammered Today Motley Fool -13.04%
Apr-05-17 07:00AM  Immunomedics Reports Sacituzumab Govitecan (IMMU-132) is Active in Patients With Metastatic Small-Cell Lung Cancer Who Are Sensitive or Resistant to First-Line Chemotherapy GlobeNewswire
07:00AM  Immunomedics Reports Sacituzumab Govitecan (IMMU-132) is Active in Patients With Metastatic Small-Cell Lung Cancer Who Are Sensitive or Resistant to First-Line Chemotherapy
Apr-04-17 01:00PM  Immunomedics Presents Preclinical Study That Demonstrates Increased SN-38 Delivery With Labetuzumab Govitecan (IMMU-130) Compared With Irinotecan GlobeNewswire
01:00PM  Immunomedics Presents Preclinical Study That Demonstrates Increased SN-38 Delivery With Labetuzumab Govitecan (IMMU-130) Compared With Irinotecan
09:24AM  Biotech Movers: Paratek Spikes 34% TheStreet.com
09:24AM  Biotech Movers: Paratek Spikes 34%
08:00AM  Immunomedics Reports Sacituzumab Govitecan (Immu-132) Delivers High Levels of sn-38 That Overcome Chemoresistant Tumors With Moderate to Strong Trop-2 Expression GlobeNewswire
08:00AM  Immunomedics Reports Sacituzumab Govitecan (Immu-132) Delivers High Levels of sn-38 That Overcome Chemoresistant Tumors With Moderate to Strong Trop-2 Expression
Mar-28-17 02:06PM  Battle in the Boardroom: What's Next for Immunomedics Motley Fool
02:06PM  Battle in the Boardroom: What's Next for Immunomedics at Motley Fool
09:30AM  Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and Immunomedics Accesswire
08:26AM  Why Shares of Immunomedics Inc Are up an Astounding 89% in 2017 Motley Fool
08:26AM  Why Shares of Immunomedics Inc Are up an Astounding 89% in 2017 at Motley Fool
Mar-21-17 03:02PM  Billionaires' Best Healthcare Stock Picks of 2017 (So Far) Motley Fool
03:02PM  Billionaires' Best Healthcare Stock Picks of 2017 (So Far) at Motley Fool
Mar-17-17 02:46PM  3 Companies That Need to Kick Their CEO to the Curb Motley Fool
02:46PM  3 Companies That Need to Kick Their CEO to the Curb at Motley Fool
Mar-16-17 01:13PM  IMMUNOMEDICS INC Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders
Mar-15-17 09:32AM  Biotech Premarket Movers: Arena, Immunomedics, Aralez
08:00AM  Immunomedics Announces Publication of Results in Journal of Clinical Oncology, Demonstrating Treatment With Sacituzumab Govitecan (IMMU-132) Produces Early and Durable Responses in Patients With Metastatic Triple-Negative Breast Cancer PR Newswire
Mar-10-17 02:27PM  Heres Whats Moving Immunomedics, Inc. (IMMU) And Ocera Therapeutics Inc (OCRX) at Insider Monkey +5.49%
02:25PM  Judge Blocks $2B Immunomedics-Seattle Genetics Deal (IMMU,SGEN) at Investopedia
09:30AM  Markets Rally Late to Close in the Green: Today's Research Reports on Immunomedics and VIVUS Accesswire
Mar-09-17 04:39PM  Why Immunomedics, Inc. Jumped Higher Today at Motley Fool +19.48%
04:37PM  Why Marathon Oil, Signet Jewelers, and Immunomedics Jumped Today at Motley Fool
04:35PM  IMMUNOMEDICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
04:24PM  Immunomedics (IMMU) Stock Soars After Deal with Seattle Genetics Is Halted
02:35PM  Judge puts Seattle Genetics' $2 billion deal with Immunomedics on hold at bizjournals.com
01:33PM  Immunomedics Soars on Injunction Against Seattle Genetics Deal
Mar-06-17 08:47AM  Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
07:48AM  Seattle Genetics to resume trials as FDA lifts clinical hold Reuters
Mar-03-17 12:21PM  Activist Investor Wins Control of Immunomedics Board Following Shareholder Vote
12:00PM  Stockholders Endorse venBios Case for Meaningful Change at Immunomedics Business Wire
11:50AM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
10:19AM  Immunomedics Board Institutes Measures As Stockholder Fiduciaries To Preserve Their Best Business Judgment To Protect The Rights Of All Stockholders PR Newswire
Mar-02-17 01:51PM  venBio Encourages Stockholders to Vote for Change Business Wire
12:06PM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
10:23AM  Immunomedics Outlines Revised Settlement Offer Rejected By venBio; Announces Actions That Are In The Best Interests Of All Stockholders PR Newswire
Feb-28-17 08:00AM  Immunomedics to Present at Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-27-17 08:24AM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  Immunomedics Issues Open Letter Highlighting the Clear Decision to Vote for Immunomedics to Ensure Continued Value Creation GlobeNewswire
Feb-23-17 05:34PM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
11:53AM  Immunomedics Sues Board Over Seattle Genetics Deal at Investopedia
11:30AM  Immunomedics Announces Companys Immune Checkpoint Inhibitor Enhances Anti-Tumor Potency of T-Cell-Redirecting Bispecific Antibodies GlobeNewswire
Feb-22-17 08:32AM  venBio Sends Letter to Immunomedics Stockholders Business Wire
Feb-21-17 08:45AM  IMMUNOMEDICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -5.24%
08:00AM  Immunomedics Files Federal Lawsuit Against venBio for Continuing Material Violations of the Federal Securities Laws GlobeNewswire
Feb-17-17 12:17PM  IMMUNOMEDICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
12:00PM  Immunomedics Presents Updated Results With Sacituzumab Govitecan (IMMU-132) in Heavily-Pretreated Patients With Metastatic Urothelial Cancer GlobeNewswire
11:21AM  VenBio Tries to Block Immunomedics Cancer Deal at Investopedia
Feb-16-17 05:02PM  IMMUNOMEDICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti
Feb-15-17 05:26PM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:15PM  Immunomedics Sends Letter to Stockholders Highlighting Value Creating Global Licensing Agreement, Underscoring Fulfillment of Promise to Stockholders GlobeNewswire
01:04PM  IMMUNOMEDICS INC Financials
11:34AM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q2, 2017 By the Numbers : February 15, 2017
Feb-14-17 08:55PM  Seattle Genetics signs $2B licensing deal with Immunomedics for cancer drug at bizjournals.com
04:47PM  Immunomedics Comments on Baseless venBio Lawsuit GlobeNewswire
12:33PM  Activist Investor to Block Partnership of Immunomedics and Seattle Genetics at TheStreet
11:50AM  venBio Takes Steps to Protect Rights of Immunomedics Stockholders Business Wire
10:56AM  Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics
01:55AM  Seattle Genetics Earnings: Waiting on ECHELON at Motley Fool
Feb-13-17 10:30AM  Heres Our Take On The Immunomedics, Inc. (IMMU) Deal at Insider Monkey
08:15AM  Blog Coverage Immunomedics Announces a $2 Billion Cancer Deal with Seattle Genetics Accesswire
Feb-12-17 11:35PM  Edited Transcript of IMMU earnings conference call or presentation 10-Feb-17 1:00pm GMT
Feb-10-17 04:14PM  venBio Comments on Immunomedics Partnership Announcement Business Wire +21.63%
10:05AM  Immunomedics, Seattle Genetics Ink $2B Cancer Deal at Investopedia
09:14AM  Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News
08:26AM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:26AM  Immunomedics Announces Postponement of 2016 Annual Meeting PR Newswire
06:50AM  Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties PR Newswire
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and epratuzumab, a humanized antibody that targets CD22, an antigen found on the surface of B lymphocytes. Its early-stage products include IMMU-114, a novel humanized antibody for the treatment of patients with B-cell and other cancers; Milatuzumab, a humanized monoclonal antibody targeting tumors that expresses the CD74 antigen, which is present on various hematological tumors and solid cancers; Veltuzumab, a humanized monoclonal antibody targeting CD20 receptors on B lymphocytes for the treatment of non-Hodgkin lymphoma and autoimmune diseases; and Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled anti-CD22 investigational product. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stark Don CDirectorAug 24Sale2.979,90029,45155,848Aug 25 05:00 PM
MARKISON BRIAN ADirectorAug 23Option Exercise1.9615,00029,40090,446Aug 25 05:01 PM
PAETZOLD MARY EDirectorAug 23Option Exercise1.9615,00029,40082,474Aug 25 05:00 PM
MARKISON BRIAN ADirectorAug 23Sale2.9815,00044,63475,446Aug 25 05:01 PM
PAETZOLD MARY EDirectorAug 23Sale2.9815,00044,67367,474Aug 25 05:00 PM
Stark Don CDirectorAug 10Option Exercise1.9615,00029,40065,748Aug 12 04:00 PM